SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compounds institutional pivotincluding a treasury-backed finance program, new leadership and an institutional market launchis fueling interest, alongside anticipation of a technical breakout tied to COMPs capped supply. Bulls see room for a rebound, while skeptics point to weak price action and concerns about liquidity and the protocols prospects.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

WLDs sharp rally and perceived technical breakout are drawing attention, with traders highlighting Eightco/ORBSs reported 8.4% stake in the token as a source of treasury-related interest. Some also point to Worldcoins proof-of-humanity angle amid AI growth, while ETF and further-upside expectations remain speculative.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Discussion centers on real-world evidence for CorMedixs DefenCath versus ClearGuard: bullish traders point to infection reductions in some studies and subgroups, while skeptics highlight Fresenius results showing no significant overall difference and question whether DefenCath justifies its higher cost. The debate feeds into broader uncertainty about DefenCath adoption and reimbursement after the temporary TDAPA payment period.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is drawing attention amid a steep selloff and repeated 52-week lows, with traders pointing to high rates, rising fuel costs and a weak housing and construction outlook, as well as concerns about acquisition financing and dilution. Bulls remain focused on Brad Jacobs building-products roll-up and long-term integration potential, while Michael Burrys reported stake prompted short-squeeze speculation; skeptics question whether that interest can offset the macro headwinds.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs sharp, high-volume breakout and close above a long-standing resistance level drew attention despite no confirmed company announcement. Traders attribute the move to possible institutional buying and short covering, while also speculating about upcoming Anktiva regulatory and commercial catalysts; the squeeze theories remain unconfirmed.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnights mainnet rollout and reported exchange listings are drawing attention, with traders also pointing to validator and institutional-use developments as potential signs of adoption. The reaction is divided: bullish holders see long-term promise in the privacy-focused network, while skeptics cite weak follow-through, airdrop-related selling and ongoing supply pressure.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Repeated revenue shortfalls and uncertainty about Harrows guidance are driving discussion, with investors questioning managements forecasting credibility and whether VEVYE and IHEEZO growth can translate into stronger sales. Bulls point to the expanding ophthalmology portfolio and potential for better execution, while skeptics are waiting for consistent results before regaining confidence.

iShares Trust - iShares 7-10 Year Treasury Bond ETF

iShares 7-10 Year Treasury Bond ETF

Treasury-yield volatility and expectations for rates to stay higher for longer dominate discussion, with traders weighing the risk of further bond-price declines against the possibility that softer jobs data and fewer expected Fed hikes could support IEF. Some are buying for income or a potential yield retreat, while others remain bearish on Treasuries.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is drawing attention amid a cybersecurity-sector rally tied to rising AI-related threat concerns, with traders also citing bullish analyst target increases and the stocks recent breakout. Many see its valuation as low relative to peers and speculate about a potential acquisition, while skeptics question its ability to sustain growth and keep pace with CrowdStrike; takeover talk remains speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


cm88betus1

CM88